The Van Andel Research Institute (VARI) has announced the expansion of its neurodegenerative disease research program, with Dr. Gerhard Coetzee and Dr. Viviane Labrie joining its Center for Neurodegenerative Science. The center’s focus is the development of new therapies for brain repair, the discovery of biomarkers, and the study of the molecular,…
Lund University researchers have shown that cerebrospinal fluid (CSF) biomarkers of angiogenesis are raised in Parkinson’s disease (PD) patients and are related to walking and balance difficulties, blood-brain barrier (BBB) increased permeability, and white matter lesions (WMLs). The research study, entitled “Increased CSF biomarkers of angiogenesis in Parkinson Disease”…
Researchers from the University of Kentucky presented the results of their research on a potential novel therapy for the treatment of Parkinson’s disease. The poster presentation, entitled “Therapeutic Development of siRNA targeting Alpha-Synuclein,” was part of the Michael J. Fox Foundation (MJFF) Parkinson’s Disease Therapeutics Conference held in…
A new case control study evaluated the association between caffeine consumption and risk of developing Parkinson’s disease (PD) in patients with high and low genetic susceptibility. The paper, entitled “Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinson’s Disease,” was published in Scientific Reports. Parkinson’s disease,…
University of Dundeen scientists have uncovered the molecular mechanisms and targets under the effect of a specific gene mutation involved in Parkinson’s disease development and which could prove to be strong targets for new therapies and even early disease detection. The paper entitled “Phosphoproteomic screening identifies Rab GTPases as novel downstream targets…
Researchers at King’s College London have identified a gene, HIFalpha, that plays a role in the regulation of nerve signals from damaged mitochondria that, in turn, affect nerve cell function, and which holds out the possibility of eventually finding a way to turn that gene off and restore function. The…
Researchers at the Georgetown University Medical Center reported nilotinib (Tasigna® by Novartis), a treatment for chronic myelogenous leukemia (CML), successfully treated Parkinson’s disease and Lewy body dementia patients in a Phase I trial. The complete results were presented during the annual meeting of the society of Neuroscience, Neuroscience 2015, held in Chicago…
Researchers at the Biotech Research and Innovation Centre (BRIC), University of Copenhagen, have linked lack of signaling by the immune system-regulating cytokine Interferon-beta (IFNβ) to the on-set of non-inheritable Parkinson’s disease (PD). The research paper, entitled “Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson’s Disease-like Dementia”, was published…
Get regular updates to your inbox.